|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||123.41 - 125.79|
|52 Week Range||90.64 - 125.79|
|Beta (3Y Monthly)||0.34|
|PE Ratio (TTM)||39.97|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||1.48 (1.19%)|
|1y Target Est||109.00|
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.
ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
More than 936 million people have obstructive sleep apnea – the disease’s first prevalence update in more than a decade – according to The Lancet Respiratory Medicine, the world’s leading journal in its field. The Lancet today published a multinational analysis by ResMed (RMD) (RMD.AX) and 12 academic leaders in sleep research. This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million, renewing calls for physicians to step up their efforts to screen, diagnose, and prescribe treatment for those who unknowingly suffer.
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
ResMed today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2019 on Thursday, July 25, 2019, after the New York Stock Exchange closes.
Today we are going to look at ResMed Inc. (NYSE:RMD) to see whether it might be an attractive investment prospect. In...
ResMed (RMD) (RMD.AX) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Measuring ResMed Inc.'s (NYSE:RMD) track record of past performance is an insightful exercise for investors. It...
ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.
ResMed today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m.
ResMed today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m.
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
.@ResMed study finds #CPAP adherence improved by remote monitoring, self-monitoring across 3 countries
Age, gender, and disease severity all impact long-term #CPAP adherence more than previously thought, according to a million-patient study shown at #ATS2019 #sleepapnea
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital SaaS solutions, today announced it has elected experienced business executive Jan De Witte to its board of directors. Mr. De Witte was appointed during ResMed’s regularly scheduled board meeting on May 16, 2019, to fill a newly created directorship, effective immediately.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Brightree® today announced plans for its Home Health and Hospice customers to access more than 50,000 provider locations and health systems nationwide via the CommonWell Health Alliance, a nonprofit national trade association of health IT companies, and through CommonWell to Carequality, a national, consensus-built common interoperability framework. This represents an important step forward in bridging the gap between out-of-hospital care providers and the broader care ecosystem, solving for when providers lose visibility into their patients’ care when they enter a post-acute care setting.